Myelin proteolipid protein (PLP) induced EAE in SJL mice results in a relapsing-remitting disease, suitable for studies of efficacy. The encephalogenic peptide aa 139-151 is emulsified in adjuvant and injected s.c. Disease can be boosted with injection of pertussis toxin. Mice develop a relapsing EAE with ascending flaccid paralysis around 1-2 weeks after immunization. Autoreactive T cells are activated in the periphery and migrate into the CNS across the blood-brain-barrier. Upon entry into the CNS, T cells are re-activated by antigen-presenting cells, ultimately resulting in demyelination and axonal cell death. PLP-induced EAE is a severe and demyelinating encephalomyelitis with a relapsing-remitting disease course. The disease is CD4+ T cell mediated and dependent on both Th1 and Th17 cells. T cells, B cells and macrophages are recruited to the inflammatory site resulting in demyelination and axonal loss. IL-17 and IFN-g responses from LNs cells can be assayed ex vivo as estimation of drug efficacy in vivo or prediction of efficacy for selection of lead compounds before in vivo experiment.